Tempus Signs Strategic Collaboration Agreement with AstraZeneca to Advance Oncology Therapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community. By combining the capabilities of a technology company with those of … Continued

Tempus Accelerates its EHR Integration Scope with Epic

Tempus expands its existing provider EHR integrations to offer physicians seamless access to its genomic testing Tempus, a leader in artificial intelligence and precision medicine, announced that it is working with Epic to offer providers in-workflow integrations at scale. Since its founding, Tempus has strived to provide physicians seamless access to next-generation sequencing and the … Continued

Tempus Incorporates OncoKB Data and NCCN Guidelines Into Its Clinical Reports

Tempus is integrating information from the Memorial Sloan Kettering Cancer Center’s OncoKB database and NCCN Guidelines into its clinical reports, providing physicians robust, well-vetted guidelines at their fingertips   Tempus, a leader in artificial intelligence and precision medicine, today announced that it will incorporate data from both the Memorial Sloan Kettering Cancer Center (MSK) OncoKB … Continued

Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year collaboration that provides Kronos Bio with access to Tempus’ real-world genomic and transcriptomic data and data analytics tools. Under the agreement, Kronos Bio will … Continued

Tempus Introduces A New, Predictive Diagnostic Test to its Growing Collection of Algorithms

Tempus’ platform brings research to life with predictive algorithms that screen cancer patients for mutations in the DPYD gene Tempus, a leader in artificial intelligence and precision medicine, today announced its new DPYD algorithm as its most recent addition to its growing collection of predictive algorithm laboratory-developed tests. The test assesses for relevant mutations in … Continued

Improving Mental Health Outcomes Through Personalized Medicine

By: Eric Lefkofsky  This week marked the thirty-first observance of Mental Illness Awareness Week, which was established in 1990 by Congress to raise awareness and education around mental health conditions. It is important to acknowledge the strides that have been made over the past three decades to destigmatize mental illness and increase access to care, … Continued

Discover Novel Targets and Applications with Tempus EXPLORE

Discover how Leap Therapeutics enhanced their understanding of a key biomarker for their clinical program in just a few months with Tempus EXPLORE, a cost-efficient research tool that provides access to the Tempus oncology database via Tempus bioinformatics experts. Watch replay from 9/30/2021.

A Patient-Centric Approach to Transforming Healthcare

By Eric Lefkofsky and Lauren Silvis We’re all patients at points in our lives. We might be looking for a different treatment option in our ongoing battle against cancer, trying to understand our risk of developing a rare heart condition, or waiting to learn whether we have a new infectious disease. At these moments, we … Continued

‘Molecular Twin’ Initiative Will Help Advance Precision Cancer Treatment

Cedars-Sinai Cancer and Tempus, a leader in artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual’s disease. By creating these “molecular twins,” scientists can genetically classify cancer genes and proteins of particular tumors obtained … Continued

Tempus Submits PMA Application to the FDA for its xT-Onco Assay

Tempus, a leader in artificial intelligence and precision medicine, today announced the submission of a Premarket Approval (PMA) application for its proprietary broad-panel DNA sequencing assay to the U.S. Food and Drug Administration (FDA).  Tempus is seeking approval for its xT-Onco assay, a broad-panel next-generation sequencing-based, in vitro diagnostic device. The submission includes companion diagnostic … Continued